ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Multifunctional Nano Immunostimulant: Overcoming Immunosuppressive Microenvironment for Antitumor Immunotherapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.Drug delivery · 2026Review
- A reduction-sensitive lipophilic dihydroartemisinin prodrug in a self-microemulsifying drug delivery system for treating breast cancer lung metastasis via intestinal lymphatic transport.International journal of pharmaceutics: X · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Antitumor immunotherapy has become a pillar therapy by activating the immune system to recognize and attack tumor cells. Yet its efficacy is limited by the immunosuppressive tumor microenvironment (TME) and related mechanisms like hypoxia, high glutathione (GSH) expression, and immune evasion. Due to TME complexity and tumor heterogeneity, monotherapy struggles to modulate immunosuppressive factors for potent results. To solve this, this work develops a multifunctional immune stimulator (3IZH), which can simultaneously boost immunity, downregulate GSH, and alleviate hypoxia. In weakly acidic TME, it releases photosensitizer (3ICy5) and Fe ions. Fe ions consume GSH and relieve hypoxia via redox reactions and hydrogen peroxide decomposition. 3ICy5 accumulates in the endoplasmic reticulum (ER), produces ROS, induces severe ER stress and DAMPs release, triggering immunogenic cell death (ICD). Fe ions and ROS also reduce glutathione peroxidase 4 (GPX4), causing ferroptosis. ICD and ferroptosis activate T cell infiltration to restructure TME. Combined with HIF-1α inhibitor digoxin, 3IZH further reduces HIF-1α resistance, enhances immune cell infiltration, and shows satisfying efficacy in bilateral tumor-bearing mice. The regulatory effect of the immune-suppressive TME, the remarkable therapeutic effect, as well as the safety profile, together indicate the potential of the multifunctional immune stimulator design strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.